![]() |
UCSF Benioff Children's Hospital Oakland Hematology/Oncology Department Research Studies Open for Enrollment |
Date: 01/26/2021 |
---|
Title | ID/Protocol | NCT/Phase | Sponsor | P.I. | Contact |
Bone Marrow Transplantation Compared to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease | BMT-CTN-1503-STRIDE2 | NCT02766465 Phase 2 | BMT-CTN, Medical College of Wisconsin | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34 Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease | HGB-206 | 02140554 Phase 1/2 | bluebird bio, Inc. | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease | BMT-CTN-1507 | NCT03263559 Phase 2 | BMT-CTN, Medical College of Wisconsin | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
Allogeneic Stem Cell Transplantation of CordIn (Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells) in Patients with Hemoglobinopathies | CordIn | NCT02504619 Phase 1/2 | Gamida Cell Ltd | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
Long Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord/CordIn, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells | NiCord | N/A | Gamida Cell Ltd | Mark Walters, MD | Julie Decaris (510-428-3385 x2739) |
Sample Collection of Bone Marrow, Blood, Peripheral Blood Stem Cells or Umbilical Cord Blood from Patients with Genetic Diseases Affecting the Blood Cells | BMT-repository | N/A | California Institute for Regenerative Medicine | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-Beta-0 Thalassemia) | Imara | NCT03401112 Phase 2a | Imara | Ward Hagar, MD | Smith, Kacie |
Anti-Sickling Agents | Anti-Sickling | N/A | UCSF BCHO | Anne Marsh, MD | Kacie Smith (510-428-3885 x2752) |
Application of the HemeChip Point of Care Device for Real-time Monitoring of Hemoglobin S Levels in Chronically Transfused Patients with Sickle Cell Disease | HemeChip | N/A | Doris Duke Charitable Foundation | Carolyn Hoppe, MD | Carolyn Hoppe, MD (510-428-3885 x3193) |
Association between Low Bone Mineral Density (BMD) and Avascular Necrosis (AVN) Chart Review Study | SCD-BMD-AVN | N/A | UCSF BCHO | Lynne Neumayr, MD | Mariam Hameed (510-428-3885 x4151) |
Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) | DISPLACE | N/A | UCSF BCHO | Carolyn Hoppe, MD | Mariam Hameed (510-428-3885 x4151) |
Efficacy and Safety of Rivipansel in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease | GMI-1070 | NCT02187003 Phase 3 | Pfizer | Lynne Neumayr, MD | Kacie Smith (510-428-3885 x2752) |
Engaging Parents of Children with Sickle Cell Disease and their Providers in Shared-Decision Making for Hydroxyurea (ENGAGE HU) | Engage-Hydroxyurea | NCT03442114 | Patient-Centered Outcomes Research Institute | Lynne Neumayr, MD | Mariam Hameed (510-428-3885 x4151) |
Prospective Study to Evaluate Disease Status in Patients with Sickle Cell Disease: Global Regional Network for Database and Discovery (GRNDaD) | GRNDaD | N/A | Doris Duke Charitable Foundation | Carolyn Hoppe, MD | Mariam Hameed (510-428-3885 x4151) |
Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riocigut in Patients with Sickle Cell Diseases | STERIO | NCT02633397 Phase 2b | University of Pittsburgh | Ward Hagar, MD | Mariam Hameed (510-428-3885 x4151) |
Sickle Cell Disease Implementation Consortium Registry: Collecting and Tracking Health Information for Patients with Sickle Cell Disease | SCCCI | N/A | National Heart, Lung and Blood Institute | Marsha Treadwell, PhD | Teleah Slater (510-428-3691) |